Drug
Inavolisib clinical trials
Also written GDC-0077, Itovebi and RO7113755.
- studies test it
- 25
- open now
- 16
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the inavolisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 8 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 20
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 9
Hoffmann-La Roche (14) · Genentech, Inc. (2) · German Cancer Research Center (2) · MedSIR (1) · Fudan University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · National Cancer Institute, Naples (1) · GBG Forschungs GmbH (1)
Often tested with
Tested in the same studies.
Atezolizumab (9) · Ipatasertib (8) · Abemaciclib (5) · Giredestrant (4) · Ado-Trastuzumab Emtansine (4) · Bevacizumab (4) · Palbociclib (4) · Fulvestrant (4)
Studies
Open first, then newest update. How each study uses inavolisib is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208Written as Inavolisib
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Written as Inavolisib
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Inavolisib (Dose #1)
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT06790693Written as Inavolisib
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07368998Written as Inavolisib
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Written as Inavolisib
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Written as Inavolisib
- A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma PatientsNot yet recruitingPhase 2Fudan UniversityNCT07694973Written as Inavolisib
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390Written as Inavolisib + Ribociclib + Fulvestrant
- Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4Not yet recruitingPhase 2National Cancer Institute, NaplesNCT07522697Written as Inavolisib
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Inavolisib
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingPhase 2German Cancer Research CenterNCT05332561Written as Inavolisib
- A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of InavolisibCompletedPhase 1Genentech, Inc.NCT07144111Written as Inavolisib
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingPhase 2MedSIRNCT05708235Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 2/3Hoffmann-La RocheNCT04191499Written as Inavolisib
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Inavolisib
See all 25 studies that test inavolisib →
Given in every arm · 5 — inavolisib is usual care beside what is tested
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Inavolisib
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Written as Inavolisib
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03006172Written as Inavolisib
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Written as Inavolisib
- A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersActive, not recruitingPhase 1Hoffmann-La RocheNCT06496568Written as Inavolisib
Codes
What other systems call inavolisib · ClinicalTrials.gg INT001966
- MeSH (NLM) C000723546inavolisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L4C1UY2NYHINAVOLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76855355inavolisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C132166InavolisibOne source FDA
- DrugBank DB15275One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723546 | inavolisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L4C1UY2NYH | INAVOLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76855355 | inavolisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C132166 | Inavolisib | One source FDA |
| DrugBank | DB15275 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.